The company’s first patent of 2020 provides protections for its Central Line Simulator, a procedural training device used by specialized physicians to practice skills related to the insertion of central venous access devices.
TAMPA, Fla. – SynDaver, an advanced bio-technology company specializing in the creation of synthetic human and animal simulators for education, medical testing and training, announced today, the U.S. Patent and Trademark Office granted U.S. Patent 10,553,131, which covers the intellectual property of the company’s Central Line Simulation and Training Device.